Project 170712

Mood Stabilizer Plus Antidepressant versus Mood Stabilizer Plus Placebo in the Maintenance Treatment of Bipolar Disorder

170712

Mood Stabilizer Plus Antidepressant versus Mood Stabilizer Plus Placebo in the Maintenance Treatment of Bipolar Disorder

$1,450,636
Project Information
Study Type: Trial Randomized_Controlled_Trial
Therapeutic Area: Mental_Health
Research Theme: Clinical
Disease Area: bipolar disorder
Data Type: Canadian
Institution & Funding
Principal Investigator(s): Yatham, Lakshmi N; Bond, David J
Co-Investigator(s): Beaulieu, Serge; Cervantes, Pablo; McIntyre, Roger S; Milev, Roumen V; Parikh, Sagar V; Ravindran, Arun; Schaffer, Ayal; Sharma, Verinder; Wong, Hubert H; Young, L. Trevor
Institution: University of British Columbia
CIHR Institute: Neurosciences, Mental Health and Addiction
Program: Randomized Controlled Trials
Peer Review Committee: Randomized Controlled Trials - A (RSA)
Competition Year: 2008
Term: 4 yrs 0 mth
Abstract Summary

People with bipolar I disorder (BDI) expereince episodes of both mania and depression. Manic episodes are characterized by unusually elevated mood, increased energy, and impulsivity, to the point that people often behave recklessly or dangerously. During depressions, in contrast, people feel unrelentingly sad, fatigued, and hopeless, and may even experience suicidal thoughts. Commonly used medications for BDI, such as mood stabilizers, are ineffective in preventing depressive episodes in large numbers of people. As a result, antidepressant medications are prescribed to up to 70% of people with BDI, and half of those people continue to take the antidepressant medications for 1 year or longer. While antidepressants in combination with mood stabilizers have been shown to treat acute depressive episodes, and to not be associated with with an increased risk of mania during short-term treatment, no well-desgned research studies have been carried out to determine if they help to prevent depression when taken during long-term treatment, or whether they might increase the frequency of manic episodes. We will carry out a randomized controlled trial to answer these questions. People with BDI who recently recovered from a depressive episode while taking a mood stabilizer and an antidepressant will keep taking their mood stabilizer, and will either continue the antidepressant for 1 year, or will replace it with a placebo (sugar pill) after 2 months. Neither the patients nor the researchers will know if the person is receiving the antidepressant or the placebo. People in the study will be followed regualrly to make sure thay are not relapsing into depression or mania. By carrying out this study, we will determine if antidepressant medications are safe and effective in preventing mood episodes during long-term treatment. If so, they will help to keep people with BDI well, and prevent the disability and frequent need for hospitaliation that is associated with depression.

Research Characteristics

This project includes the following research characteristics:

Health Technology Assessment
Resource Utilization
Productivity Outcomes
Policy Evaluation
Patient Reported Outcomes
Multicenter
Knowledge Translation Focus
Safety Focus
Quality of Life
Time to Event
Composite Endpoint
Vulnerable Populations
Combination Therapy
Study Justification

"determine if antidepressant medications are safe and effective in preventing mood episodes during long-term treatment"

Novelty Statement

"no well-desgned research studies have been carried out to determine if they help to prevent depression when taken during long-term treatment, or whether they might increase the frequency of manic episodes"

Methodology Innovation

randomized placebo-controlled trial evaluating long-term antidepressant use in bipolar disorder maintenance

Keywords
Antidepressant Bipolar Disorder Maintenance Treatment Mood Stabilizer Randomized Controlled Trial